Melinta Therapeutics (MLNTQ) Stock Price, News & Analysis

Company Overview

Melinta Therapeutics is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel anti-infective therapies targeting multi-drug resistant Gram-negative and Gram-positive pathogens. The company’s product portfolio includes two approved agents: delafloxacin (Baxdela), indicated for acute bacterial skin and skin structure infections, and the carbapenem–β-lactamase inhibitor combination meropenem-vaborbactam (Vabomere), approved for complicated urinary tract infections. Melinta’s research platform emphasizes structure-based drug design and optimization to advance compounds with unique mechanisms of action against resistant bacteria.

Headquartered in New Haven, Connecticut, Melinta operates commercial teams to support hospital accounts and acute care settings across the United States, while forging partnerships to extend its reach in international markets. In addition to its marketed products, the company maintains a robust clinical pipeline, with programs investigating treatments for hospital-acquired bacterial pneumonia, sepsis and other critical infections. Melinta’s manufacturing and research facilities work in tandem to ensure both supply chain reliability and continued innovation.

Founded in 2013 as a spin-out from The Medicines Company, Melinta Therapeutics completed its initial public offering in 2015. In 2019, the company underwent a financial restructuring to streamline operations and enhance its focus on core antibiotic franchises. Today, Melinta is privately held and supported by institutional and strategic investors, with an experienced management team driving its mission to address the growing threat of antimicrobial resistance.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.11 to $0.11
• 52-Week Range: $0.06 to $8.60
• Volume: 32,900 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MLNTQ Stock Analysis - Frequently Asked Questions

How have MLNTQ shares performed this year?

Melinta Therapeutics' stock was trading at $0.11 at the start of the year. Since then, MLNTQ stock has increased by 0.0% and is now trading at $0.11.

How do I buy shares of Melinta Therapeutics?

Shares of MLNTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MLNTQ
• CIK: N/A
• Web: www.melinta.com
• Phone: 908-617-1309
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A